Bio / Bio Monthly (June 2025): Bio x AI Winners, Human Trials, GitHub for IP, Longevity Gene Therapy

EcosystemJuly 3, 2025

Bio Monthly (June 2025): Bio x AI Winners, Human Trials, GitHub for IP, Longevity Gene Therapy

The winners of the 2-month virtual Bio x AI hackathon have been announced. VitaDAO and CerebrumDAO are rapidly progressing toward animal and human trials. Molecule Labs has launched a "Github for tokenized IP".

By Bio Community

Bio Monthly (June 2025): Bio x AI Winners, Human Trials, GitHub for IP, Longevity Gene Therapy

🌐 Highlights from the last month in the Biosphere 🌐

The Bio x AI Hackathon winners were announced, receiving $125K in prizes. The 2-month virtual hackathon saw over 60 teams build scientific agents, giving a glimpse into what's coming as scientific AI moves onchain and Bio gears up for its first "BioAgent" launches.
Several biotech assets in the Bio ecosystem are rapidly progressing towards animal and human trials, including VitaDAO’s gene therapy VitaRNA, and CerebrumDAO’s brain supplement Percepta. These assets are advancing to trials in months, not years, and at a fraction of the cost compared to traditional biotech, with monetization flowing back to their respective BioDAOs.
Molecule Labs launched a "Github for tokenized IP" to enable research teams to manage, publish and update onchain scientific data in real-time with granular visibility controls.
DeSci Berlin gathered industry leaders and investors for a 2-day event, featuring a keynote from renowned MIT Professor Ed Boyden as well as speakers from Bio, MetaMask, VitaDAO, Harvard, Solana, 1kx, OriginTrail & more. Watch the talks on our Youtube.

👾 Bio x AI Hackathon Hackathon Winners

Bio's 2-month virtual hackathon saw over build DeSci agents for polymorphic prediction, microbiome advice, knowledge graph creation and more. Winners were announced during a , featuring live agent demos, Q&A and a panel on the future of agentic science with elizaOS and OriginTrail.

Curetopia's ARS pipeline is rapidly advancing, highlighted by a successful YARS2 TargetMol screen and promising data from half of their ten target screens, indicating potential treatments for an entire family of diseases. They anticipate completing the remaining screens by the end of July and hit validation studies by September. Simultaneously, Curetopia is preparing to utilize AI for novel discoveries, initiate patent filings for their initial assets, and develop a portfolio of ARS IP-NFTs this summer, aiming to bundle them for future pharmaceutical partnerships. These efforts are foundational to their extensive ~40 ARS disease pipeline, as outlined in their Q2 Research Plan proposal.
Long COVID Labs founder, Rohan Dixit, shared that they are building an open-source patient data registry, powered by at-home kits and blood draws. LCL is currently researching SARS-CoV-2 viral persistence biomarkers to improve Long COVID diagnosis and management, with donors receiving COVID token airdrops as a reward. LCL also passed a proposal to conduct the COVID token's transferability in September 2025.
VitaDAO-funded research published in Aging Cell identified LAMP1 as a cell-surface biomarker for senescent cells, demonstrating a 2-3x increase in aged mouse organs and a 6% to 23% rise in bleomycin-induced lung fibrosis, while an antibody-drug conjugate effectively targets LAMP1+ cells, offering potential for aging-related diseases.
SpineDAO launched their Spinediana Quest, giving users tokens rewards for contributing to DAO's decentralized knowledge graph (DKG). SpineDAO's quest is an early example of how crypto incentives can produce powerful decentralized health datasets and AI agents that ultimately drive revenue to the DAO.
Pump Science announced the upcoming launch of 17 new compounds. They also introduced the Bonding curve-AMM Dual Anti-Sniper Suite, a three-phase strategy featuring high initial fees, a gradual fee reduction, and token migration, leveraging Meteora’s Dynamic Bonding Curve to effectively deter sniper bots and safeguard users during token launches.
Quantum Biology DAO are doing initial research on an engineered magnetosensitive protein, aimed at detecting magnetosensitivity in bacterial colonies. They are also designing a MEMS-based sensing system for mapping magnetic fields in a 96-well plate, enhancing precision in biological assays.
HairDAO are conducting lab experiments to evaluate olanzapine, an antipsychotic, for its potential to stimulate hair growth & tested T3 on human hair follicles showing growth-promoting effects. They also launched Topical Tretinoin on their Telehealth platform promoting keratinocyte turnover, enhancing minoxidil absorption, and reducing scalp oxidative stress.
AthenaDAO hosted the London Science Forum, showcasing pioneering work by experts on IVF advancements and ovarian tissue transplantation to delay menopause. They also hosted a Demo Day, featuring projects in ReproTech, Menopause, and AI for Fertility, where they announced an upcoming decentralized clinical trial to test Ovul's saliva hormone tracker & AthenaBIO, an equity-based fund for translational science.
PsyDAO hosted an exclusive meeting for PSY holders with DMT researcher Dr. Andrew Gallimore, to discuss funding for his new project. They also crafted their pilot batch of Kené Wasté tinctures, each with an IP equity token tied to it, timed for their booth setup at the Psychedelic Science conference in Denver.
MicrobiomeDAO won a $1,000 Interdisciplinary Longevity Track Bounty sponsored by Avinasi Labs.
Molecule has been featured in the European HealthTech Market Map 2025, among leading innovators in digital care and digital pharma across Europe.